Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Novel strategy for the use of leptin for obesity therapy.

Tam CS, Lecoultre V, Ravussin E.

Expert Opin Biol Ther. 2011 Dec;11(12):1677-85. doi: 10.1517/14712598.2011.619974. Epub 2011 Sep 13. Review.

2.

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C.

Obesity (Silver Spring). 2009 Sep;17(9):1736-43. doi: 10.1038/oby.2009.184. Epub 2009 Jun 11.

3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development.

Chan JL, Roth JD, Weyer C.

J Investig Med. 2009 Oct;57(7):777-83. doi: 10.2310/JIM.0b013e3181b91911. Review.

PMID:
20029268
5.

Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.

Kusakabe T, Ebihara K, Sakai T, Miyamoto L, Aotani D, Yamamoto Y, Yamamoto-Kataoka S, Aizawa-Abe M, Fujikura J, Hosoda K, Nakao K.

Am J Physiol Endocrinol Metab. 2012 Apr 15;302(8):E924-31. doi: 10.1152/ajpendo.00198.2011. Epub 2012 Jan 24.

6.

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.

Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ.

Obesity (Silver Spring). 2010 Sep;18(9):1739-46. doi: 10.1038/oby.2009.478. Epub 2010 Jan 21.

7.

Anti-obesity drugs: a review about their effects and their safety.

Derosa G, Maffioli P.

Expert Opin Drug Saf. 2012 May;11(3):459-71. doi: 10.1517/14740338.2012.675326. Epub 2012 Mar 23. Review.

PMID:
22439841
8.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
9.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
10.

[Combination therapy of amylin and leptin].

Furuta H.

Nihon Rinsho. 2012 May;70 Suppl 3:740-5. Japanese. No abstract available.

PMID:
22768608
11.

The role of pramlintide for weight loss.

Dunican KC, Adams NM, Desilets AR.

Ann Pharmacother. 2010 Mar;44(3):538-45. doi: 10.1345/aph.1M210. Epub 2010 Feb 17. Review.

PMID:
20164472
12.

Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.

Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M; Author Group.

Diabetes Obes Metab. 2005 Nov;7(6):755-61.

PMID:
16219020
13.

[The pharmacological treatment of obesity: past, present and future].

Simonyi G, Pados G, Medvegy M, Bedros JR.

Orv Hetil. 2012 Mar 11;153(10):363-73. doi: 10.1556/OH.2012.29317. Review. Hungarian.

PMID:
22370224
14.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112
15.

Latest approaches for the treatment of obesity.

Jackson VM, Breen DM, Fortin JP, Liou A, Kuzmiski JB, Loomis AK, Rives ML, Shah B, Carpino PA.

Expert Opin Drug Discov. 2015;10(8):825-39. doi: 10.1517/17460441.2015.1044966. Epub 2015 May 12. Review.

PMID:
25967138
16.

What are the risks and the benefits of current and emerging weight-loss medications?

Robinson JR, Niswender KD.

Curr Diab Rep. 2009 Oct;9(5):368-75. Review.

PMID:
19793507
17.

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations.

Roth JD, Trevaskis JL, Turek VF, Parkes DG.

Brain Res. 2010 Sep 2;1350:86-94. doi: 10.1016/j.brainres.2010.01.027. Epub 2010 Jan 21. Review.

PMID:
20096672
18.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
19.

[Recent progress and novel perspectives on obesity pharmacotherapy].

Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A.

Arq Bras Endocrinol Metabol. 2010 Aug;54(6):516-29. Review. Portuguese.

20.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

Items per page

Supplemental Content

Write to the Help Desk